Selective RET inhibitor selpercatinib doubles progression-free survival in RET-mutated NSCLC Presented ByProf. Herbert Ho Fung Loong, Chinese University of Hong Kong, China TrialPhase 3, LIBRETTO-431 ConferenceESMO 2023 19 December, 2023 09:54